Southampton Clinical Trials Unit, University of Southampton, Southampton, UK.
The Christie NHS Foundation Trust, Manchester, UK.
Clin Oncol (R Coll Radiol). 2021 May;33(5):e225-e231. doi: 10.1016/j.clon.2020.12.010. Epub 2021 Jan 2.
Self-expanding metal stents provide rapid improvement of dysphagia in oesophageal cancer but are associated with complications. The aim of the present study was to test the effectiveness of an alternative treatment of combining biodegradable stents with radiotherapy.
A Simon two-stage single-arm prospective phase II trial design was used to determine the efficacy of biodegradable stents plus radiotherapy in patients with dysphagia caused by oesophagus cancer who were unsuitable for radical treatment. Fourteen patients were recruited and data from 12 were included in the final analyses.
Five of 12 patients met the primary end point: one stent-related patient death; four further interventions for dysphagia within 16 weeks of stenting (41.7%, 95% confidence interval 15.2-72.3%). The median time to a 10-point deterioration of quality of life was 2.7 weeks. Nine patients died within 52 weeks of registration. The median time to death from any cause was 15.0 weeks (95% confidence interval 9.6-not reached).
The high re-intervention observed, which met the pre-defined early stopping criteria, meant that the suggested alternative treatment was not sufficiently effective to be considered for a larger scale trial design. Further work is needed to define the place of biodegradable stents in the management of malignant oesophageal strictures.
自膨式金属支架可迅速改善食管癌患者的吞咽困难,但与并发症相关。本研究旨在检验生物可降解支架联合放疗治疗食管癌所致吞咽困难的有效性。
采用 Simon 两阶段单臂前瞻性二期试验设计,确定生物可降解支架联合放疗对不适合根治性治疗的食管癌吞咽困难患者的疗效。共招募了 14 名患者,其中 12 名患者的数据被纳入最终分析。
12 名患者中有 5 名达到了主要终点:1 例支架相关患者死亡;4 例在支架置入后 16 周内因吞咽困难再次干预(41.7%,95%置信区间 15.2-72.3%)。生活质量恶化 10 分的中位时间为 2.7 周。9 例患者在注册后 52 周内死亡。任何原因导致的死亡中位时间为 15.0 周(95%置信区间 9.6-未达到)。
观察到的高再干预率达到了预先设定的早期停止标准,这意味着所建议的替代治疗方法不够有效,不能考虑用于更大规模的试验设计。需要进一步研究来确定生物可降解支架在恶性食管狭窄治疗中的地位。